Meghalaya Magazine

Primary Biliary Cirrhosis Pipeline Drugs and Companies Insight Report, 2023 Updates: Analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments

 Breaking News
  • No posts were found

Primary Biliary Cirrhosis Pipeline Drugs and Companies Insight Report, 2023 Updates: Analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments

March 07
19:37 2023
Primary Biliary Cirrhosis Pipeline Drugs and Companies Insight Report, 2023 Updates: Analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments
Las Vega (Nevada), United States //— As per DelveInsight’s assessment, globally, Primary Biliary Cirrhosis pipeline constitutes 25+ key companies continuously working towards developing 25+ Primary Biliary Cirrhosis treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

Primary Biliary Cirrhosis Overview

Primary biliary cirrhosis (PBC) is a chronic and slowly progressive cholestatic liver disease of autoimmune etiology characterized by injury of the intrahepatic bile ducts that may eventually lead to liver failure. Affected individuals are usually in their fifth to seventh decades of life at time of diagnosis, and 90% are women.

 

Primary Biliary Cirrhosis Pipeline Insight, 2023 report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Primary Biliary Cirrhosis Market.

 

The Primary Biliary Cirrhosis Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

 

Some of the key takeaways from the Primary Biliary Cirrhosis Pipeline Report:

  • Companies across the globe are diligently working toward developing novel Primary Biliary Cirrhosis treatment therapies with a considerable amount of success over the years. Primary Biliary Cirrhosis Key players such as – Parvus Therapeutics, Selecta Biosciences, Hepagene Therapeutics, Ohara Pharmaceutical, Cour Pharmaceutical, Mirum Pharmaceuticals, Gannex Pharma, Dr Falk Pharma, Genfit, CymaBay Therapeutics, and others, are developing therapies for the Primary Biliary Cirrhosis treatment 
  • Primary Biliary Cirrhosis Emerging therapies such as – PVT-201, PDC-E2, HPG-1860, OP-724, CNP-104, Volixibat, ASC42, Norucholic acid, Elafibranor, Seladelpar, and others are expected to have a significant impact on the Primary Biliary Cirrhosis market in the coming years.   
  • In January 2023, CymaBay Therapeutics, Inc. announced that it has entered into a collaboration and license agreement with Kaken Pharmaceutical Co., Ltd. for the development and commercialization in Japan of CymaBay’s investigational drug seladelpar for the treatment of primary biliary cholangitis
  • In July 2022, CymaBay announced that FDA lifted clinical holds on seladelpar for all three IND applications in NASH, PBC, and PSC. Earlier, in November 2019, the FDA had placed a hold on all active INDs of seladelpar after atypical histologic findings with no clinical or laboratory correlate identified from the Phase II NASH study
  • In August 2022, Ascletis Pharma Inc.-owned Gannex Pharma Co., Ltd. reported that the Farnesoid X Receptor agonist ASC42 for the treatment of PBC had completed its first dosage in the US drug-drug interaction (DDI) study. Future phase III trials in the US, China, and the EU will have more support thanks to the DDI study and continuing phase II clinical trial in PBC patients in China
  • In April 2021, CymaBay Therapeutics placebo-controlled, randomized, Phase III study to evaluate the efficacy and safety of seladelpar in patients with Primary Biliary Cholangitis (PBC) and an inadequate response to or an intolerance toursodeoxycholic acid (UDCA)

 

Route of Administration

Primary Biliary Cirrhosis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as 

  • Intra-articular
  • Intraocular
  • Intrathecal 
  • Intravenous
  • Ophthalmic
  • Oral
  • Parenteral
  • Subcutaneous
  • Topical
  • Transdermal

 

Molecule Type

Products have been categorized under various Molecule types, such as

  • Oligonucleotide
  • Peptide
  • Small molecule

 

Primary Biliary Cirrhosis Pipeline Therapeutics Assessment

  • Primary Biliary Cirrhosis Assessment by Product Type
  • Primary Biliary Cirrhosis By Stage and Product Type
  • Primary Biliary Cirrhosis Assessment by Route of Administration
  • Primary Biliary Cirrhosis By Stage and Route of Administration
  • Primary Biliary Cirrhosis Assessment by Molecule Type
  • Primary Biliary Cirrhosis by Stage and Molecule Type

 

DelveInsight’s Primary Biliary Cirrhosis Report covers around 25+ products under different phases of clinical development like-

  • Late-stage products (Phase III)
  • Mid-stage products (Phase II)
  • Early-stage product (Phase I)
  • Pre-clinical and Discovery stage candidates
  • Discontinued & Inactive candidates
  • Route of Administration

 

Some of the key companies in the Primary Biliary Cirrhosis Therapeutics Market include:

Key companies developing therapies for Primary Biliary Cirrhosis are – Genfit, CymaBay Therapeutics, Calliditas Therapeutics, Zydus-Cadila, Cour Pharmaceutical, Mirum Pharmaceuticals, HighTide Biopharma, PRISM Pharma Co, Albireo Pharma, Pliant Therapeutics, GentiBio, Gannex Pharma, Selecta Biosciences, Intercept Pharmaceuticals, Umecrine Cognition, Suzhou Zelgen Biopharmaceuticals, Merck Sharp & Dohme LLC, Kowa Pharmaceuticals, and others.

 

Emerging Primary Biliary Cirrhosis Drugs Under Different Phases of Clinical Development Include:

  • PVT-201: Parvus Therapeutics
  • PDC-E2: Selecta Biosciences
  • HPG-1860: Hepagene Therapeutics
  • OP-724: Ohara Pharmaceutical
  • CNP-104: Cour Pharmaceutical
  • Volixibat: Mirum Pharmaceuticals
  • ASC42: Gannex Pharma
  • Norucholic acid: Dr Falk Pharma
  • Elafibranor: Genfit
  • Seladelpar: CymaBay Therapeutics

 

Get a Free Sample PDF Report to know more about Primary Biliary Cirrhosis Pipeline Therapeutic Assessment- https://www.delveinsight.com/sample-request/primary-biliary-cirrhosis-pipeline-insight

 

Primary Biliary Cirrhosis Pipeline Analysis:

The Primary Biliary Cirrhosis pipeline report provides insights into 

  • The report provides detailed insights about companies that are developing therapies for the treatment of Primary Biliary Cirrhosis with aggregate therapies developed by each company for the same.
  • It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Primary Biliary Cirrhosis Treatment.
  • Primary Biliary Cirrhosis key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
  • Primary Biliary Cirrhosis Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 
  • Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Primary Biliary Cirrhosis market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

 

Further Primary Biliary Cirrhosis product details are provided in the report. Download the Primary Biliary Cirrhosis pipeline report to learn more about the emerging Primary Biliary Cirrhosis therapies

 

Primary Biliary Cirrhosis Pipeline Market Drivers

  • Increasing Cases of Primary Biliary Cirrhosis
  • Increasing demand for effective treatment
  • Increasing drug pipeline and FDA approval

 

Primary Biliary Cirrhosis Pipeline Market Barriers

  • High cost of the Primary Biliary Cirrhosis treatment
  • Challenging clinical trial study
  • Lacking consensus stratification protocol to identify patients for second line treatment

 

Scope of Primary Biliary Cirrhosis Pipeline Drug Insight    

  • Coverage: Global
  • Key Primary Biliary Cirrhosis Companies: Parvus Therapeutics, Selecta Biosciences, Hepagene Therapeutics, Ohara Pharmaceutical, Cour Pharmaceutical, Mirum Pharmaceuticals, Gannex Pharma, Dr Falk Pharma, Genfit, CymaBay Therapeutics, and others
  • Key Primary Biliary Cirrhosis Therapies: PVT-201, PDC-E2, HPG-1860, OP-724, CNP-104, Volixibat, ASC42, Norucholic acid, Elafibranor, Seladelpar, and others
  • Primary Biliary Cirrhosis Therapeutic Assessment: Primary Biliary Cirrhosis current marketed and Primary Biliary Cirrhosis emerging therapies
  • Primary Biliary Cirrhosis Market Dynamics: Primary Biliary Cirrhosis market drivers and Primary Biliary Cirrhosis market barriers 

 

Request for Sample PDF Report for Primary Biliary Cirrhosis Pipeline Assessment and clinical trials

 

Table of Contents

1

Primary Biliary Cirrhosis Report Introduction

2

Primary Biliary Cirrhosis Executive Summary

3

Primary Biliary Cirrhosis Overview

4

Primary Biliary Cirrhosis- Analytical Perspective In-depth Commercial Assessment

5

Primary Biliary Cirrhosis Pipeline Therapeutics

6

Primary Biliary Cirrhosis Late Stage Products (Phase II/III)

7

Primary Biliary Cirrhosis Mid Stage Products (Phase II)

8

Primary Biliary Cirrhosis Early Stage Products (Phase I)

9

Primary Biliary Cirrhosis Preclinical Stage Products

10

Primary Biliary Cirrhosis Therapeutics Assessment

11

Primary Biliary Cirrhosis Inactive Products

12

Company-University Collaborations (Licensing/Partnering) Analysis

13

Primary Biliary Cirrhosis Key Companies

14

Primary Biliary Cirrhosis Key Products

15

Primary Biliary Cirrhosis Unmet Needs

16 

Primary Biliary Cirrhosis Market Drivers and Barriers

17

Primary Biliary Cirrhosis Future Perspectives and Conclusion

18

Primary Biliary Cirrhosis Analyst Views

19

Appendix

20

About DelveInsight

*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.

 

Download Sample PDF Report to know more about Primary Biliary Cirrhosis drugs and therapies

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/consulting/r-and-d-analysis